Intrinsik levels (of unmanageable most 2100 malignan hepatocellular patients with advanced solid tumors (12 Platelet count < 100 x 10

ANG1005 is an antibody-drug conjugate (ADC) for in vivo therapy of human diseases. In this study, we report the results of ANG1005 in patients with advanced solid tumors and metastatic brain cancer.

The primary objectives of the study were to assess the antitumor activity and safety of ANG1005 in patients with advanced solid tumors and metastatic brain cancer.

INTRODUCTION

The study was a multi-center, single-arm, open-label, phase 1 study designed to assess the safety and tolerability of ANG1005 in patients with advanced solid tumors and metastatic brain cancer. The study was conducted at multiple sites in the United States.

Patient Inclusion Criteria

• Any age, sex, and race

Patient Exclusion Criteria

• Known allergic or hypersensitivity reaction to ANG1005 or any component of the formulation

The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Approval was obtained from the Institutional Review Board at each site before the study was initiated.

METHODS

The study was conducted in two phases:

Phase 1: Dose Escalation

• Dosing: ANG1005 was administered as a 2-hour intravenous infusion on a weekly basis. The starting dose was 10 mg/m² and the dose was escalated by 10 mg/m² in increments until a maximum tolerated dose (MTD) was reached.

Phase 2: Expansion

• Dosing: Patients were treated at the MTD or the dose level immediately below the MTD.

The study was terminated after the last patient had been enrolled and followed for the planned duration.

SAFETY RESULTS / PK DATA

No dose-limiting toxicities were observed. The most common adverse events included neutropenia, thrombocytopenia, and anemia. There were no unexpected adverse events.

TUMOR RESPONSE DATA

• 1 pt PR at 12 wks

CONCLUSIONS

• ANG1005 shows promise as a novel therapeutic option for patients with advanced solid tumors and brain cancer.

• Further studies are needed to evaluate the efficacy and safety of ANG1005 in larger patient populations.

• The study was sponsored by ANGIOChem, Inc.

• The study was conducted under the guidance of the Institutional Review Board at each site.

• The study was supported by the National Institutes of Health and the Department of Defense.

• The study was presented at the American Society for Clinical Oncology Annual Meeting.